Peptide Cancer Vaccines: From Neoantigen Discovery to Immune Checkpoint Combination Therapy | Research

The takeaway

A comprehensive review covers peptide cancer vaccine evolution from neoantigen discovery through immune checkpoint synergy, positioning them as precision oncology tools.

Vaccine-checkpoint synergy
Combining peptide vaccines with immune checkpoint inhibitors enhances anti-tumor immunity

What the researchers found

Peptide cancer vaccines combined with immune checkpoint inhibitors show enhanced anti-tumor responses, representing a promising personalized oncology approach.

Why it matters

Peptide vaccines could provide personalized, non-invasive cancer treatment that activates the patient's own immune system against their specific tumor.

How the study worked

Comprehensive review of peptide cancer vaccine development, neoantigen identification, and immune checkpoint synergy strategies.

What this study cannot tell us

Review — many combinations are in early clinical trials; manufacturing personalized vaccines is complex and expensive; not all tumor types are equally amenable.

How to read the evidence

Comprehensive review — synthesizes the evolving field from preclinical through clinical evidence.

When this study was published

Published 2026 in Scandinavian Journal of Immunology.

The bigger picture

The convergence of neoantigen sequencing, peptide engineering, and checkpoint immunotherapy is creating a new paradigm for precision cancer treatment.

Questions still open

Which cancer types respond best to peptide vaccine-checkpoint combinations?
Can manufacturing be scaled for widespread personalized vaccine delivery?

Common questions

What are peptide cancer vaccines?

They are vaccines made from short protein fragments (peptides) that match markers specific to a patient's tumor. The vaccine trains the immune system to recognize and attack cells displaying these markers.

Why combine vaccines with checkpoint inhibitors?

Checkpoint inhibitors "release the brakes" on the immune system, while vaccines "give it a target." Together, they can produce stronger anti-tumor immune responses than either approach alone.

Read the original research

From Neoantigen Discovery to Immune-Checkpoint Synergy: Peptide Cancer Vaccines as Precision Tools for Personalised Cancer Therapy.

Scandinavian journal of immunology, 103(1), e70084

View on PubMed ↗Publisher’s paper ↗

Citation

Banday, Abid H; Manzoor, Meer Mehru; Nissar, Urooj; Jaleel, Seeham. (2026). From Neoantigen Discovery to Immune-Checkpoint Synergy: Peptide Cancer Vaccines as Precision Tools for Personalised Cancer Therapy.. Scandinavian journal of immunology, 103(1), e70084. https://doi.org/10.1111/sji.70084